

CARBON REDUCTION PLAN

Supplier name: **Neuraxpharm UK Ltd**

Publication date: **22nd May 2026**

Commitment to achieving Net Zero

Neuraxpharm UK Ltd is committed to achieving Net Zero emissions by **2050**.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and are the reference point against which emissions reductions can be measured.

Current Baseline

Additional Details relating to the Baseline Emissions calculations.	
<p><i>2022 was the first year of reporting and therefore established a new baseline. Neuraxpharm UK Ltd had not previously reported their GHG Emissions. Due to a change in methodology, 2024 is the current baseline.</i></p> <p><i>The baseline includes Scope 1, Scope 2, and the subset of Scope 3 as described in the central UK Government's PPN 006.</i></p>	
Reporting Year: 2024	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	0.00
Scope 2	1.13
Scope 3 (Included Sources)	816.52
Total Emissions	817.79

Current Emissions Reporting

Reporting Year: 2025	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	0.00
Scope 2	2.81
Scope 3 (Included Sources)	1107.66
Total Emissions	1110.47

Trends

GHG emissions from 2025 have increased in almost all of the reporting areas in comparison to 2024, rising from 817.79 tCO₂e to 1110.47 tCO₂e, which equates to a 35.8% increase. Table 1.1 presents a comparison of greenhouse gas emissions, measured in tCO₂e, between 2024 and 2025.

Table 1.1

Scope	Category	tCO ₂ e			
		2024	2025	2025 compared to 2024	2025 categories as a percentage of overall emissions
Scope 2	Category 2: Indirect GHG emissions from imported energy				
	2.2 Indirect emissions from imported energy	1.13	2.81	148.4%	0.25%
Scope 3	Category 3: Indirect GHG emissions from transportation				
	3.1 Emissions from upstream transport and distribution for goods	161.01	176.47	9.6%	15.89%
	3.2 Emissions from downstream transport and distribution for goods	577.19	778.26	34.8%	70.08%
	3.1 & 3.2 Emissions from upstream and downstream	738.20	954.73	29.3%	85.98%
	3.3 Emissions from employee commuting	28.99	39.76	37.2%	3.58%
	3.5 Emissions from business travel	49.33	113.07	129.2%	10.18%
	Category 4: Indirect GHG emissions from products used by the organisation				
	4.3 Emissions from disposal of solid and liquid waste	0.14	0.08	-38.2%	0.008%
	4.4 Emissions from use of assets	0.002	0.015	640.5%	0.001%
	Total	817.79	1110.47	35.8%	

Within Scope 2, indirect emissions from imported energy increased from 1.13 tCO₂e in 2024 to 2.81 tCO₂e in 2025, reflecting an increase of 148.4%. Despite this sharp percentage rise, the category contributed only 0.25% of total emissions in 2025, indicating that imported energy remained a relatively minor source of emissions overall. This increase was largely due to the move into a larger office part-way through the year.

The most significant contributor to emissions was Scope 3, specifically transportation and distribution activities. Emissions from upstream transport and distribution for goods increased from 161.01 tCO₂e to 176.47 tCO₂e, representing a 9.6% rise. More notably, downstream transport and distribution emissions increased by 34.8%, from 577.19 tCO₂e in 2024 to 778.26 tCO₂e in 2025. Combined upstream and downstream transportation emissions reached 954.73 tCO₂e, accounting for 85.98% of total emissions in 2025. This demonstrates that distribution activities continue to dominate the organisation's indirect and overall emissions.

Additional increases were observed in employee commuting and business travel. Emissions associated with employee commuting rose from 28.99 tCO₂e to 39.76 tCO₂e, an increase of 37.2%. Business travel emissions showed an even more substantial rise, increasing from 49.33 tCO₂e in 2024 to 113.07 tCO₂e in 2025, representing a 129.2% increase. This can partly be attributed to the increase in the number employees between 2024 and 2025, growing from 23 to 31.

Emissions from the disposal of solid and liquid waste decreased by 38.2%, falling from 0.14 tCO₂e to 0.08 tCO₂e. Meanwhile, emissions from the use of assets increased from 0.002 tCO₂e to 0.015 tCO₂e, representing a 640.5% increase. However, the absolute emissions value remained negligible, contributing only 0.008% and 0.001% respectively of total emissions.


Overall, the data indicates that the organisation experienced considerable growth in indirect GHG emissions in 2025, driven primarily by increases in emission from business travel, emissions from downstream transportation and distribution, and emissions from employee commuting. Transportation-related activities remain the dominant source of emissions and therefore may represent the most significant opportunity for future emissions reduction initiatives.

Emissions reduction targets

The Neuraxpharm's manufacturing plant, Neuraxpharm Pharmaceuticals, which has the most notable environmental impact within the Group, has defined in 2025 a Science-Based Reduction Plan aligned with SBTi methodologies, using 2024 as the base year and 2030 as the target year. The plan covers Scopes 1 and 2 and aims to achieve at least a 42% reduction in combined emissions compared to the base year through energy efficiency measures and the progressive purchase of renewable energy (GoOs), with annual monitoring of key KPIs. At Group level, Neuraxpharm is also working to align with the European Climate Law and progress towards climate neutrality by 2050

The historical GHG emissions emitted in 2022, 2023, 2024 and 2025 are displayed in Graph 1 overleaf.

Graph 1



Carbon Reduction Projects

In 2023, Neuraxpharm initiated the calculation of their carbon footprint (scopes 1, 2 and 3) of all affiliates at Group level with an external specialised entity. In 2025, we have calculated our third total carbon footprint (Scopes 1, 2 and 3). Our carbon footprint results will serve as a critical basis for developing a plan to reduce our environmental impact and emissions over the next 18 months.

In the 2025 assessment (published in February 2026), Neuraxpharm’s manufacturing facility, Neuraxpharm Pharmaceuticals, was awarded the Bronze Medal by international CSR ratings agency, EcoVadis, a globally recognised CSR rating agency that assesses sustainability across four themes: Environment, Ethics, Labour & Human Rights, and Sustainable Procurement. The plant achieved an overall score of 70/100, improving by three points compared to the previous year (67/100) and reaching the 82nd percentile. Link to EcoVadis scorecard: <https://recognition.ecovadis.com/5TlId92HvkWaFW4mfBaxeQ>.

Furthermore, in 2025 the Group sought to reduce their reliance on non-renewable energy. This initiative led to an increase in renewable energy usage of 288% compared to 2024.

In parallel, Neuraxpharm continues to implement paperless initiatives to reduce environmental impact. The e-signature tool is available across the Group to limit paper use and courier shipments, and the rollout of the CRM-OCE tool has been expanded to fifteen countries, enabling digital engagement with healthcare professionals and reducing reliance on printed materials

On a communications level, awareness campaigns are being promoted in the workplace to encourage responsible consumption of water and electricity, as well as proper waste segregation.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors.

Signed on behalf of the Supplier:

DocuSigned by:
Mark Slater
1871A1B5559F425...

Date: 22/05/2026

Country Manager

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>